Biogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executive

Oct. 18, 2022 10:20 AM ETBiogen Inc. (BIIB)RHHBY, ESALY, ESALF, RHHBF, ACIUBy: Dulan Lokuwithana, SA News Editor5 Comments

Alzheimer"s disease: the amyloid-beta peptide accumulates to amyloid fibrils that build up dense amyloid plaques.

selvanegra/iStock via Getty Images

Following the company's Q3 2022 earnings on Tuesday, a senior executive at Roche (OTCQX:RHHBY) (OTCQX:RHHBF) told analysts that a recent data readout from Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.